Antibacterial prophylaxis during neutropenic phase in autologous peripheral blood stem cell transplant (APBSCT). comparison between ciprofloxacin + amoxicilin vs. levofloxacin  by Karduss, A.J. et al.
sion was made at 14 days after pts completed velafermin adminis-
tration with no dose limiting toxicity reported. All abnormal he-
matology or chemistry laboratory reports were expected and con-
sistent with pt disease conditions. The second cohort of 0.1 mg/kg
dose is ongoing with 2 pts completed study drug infusion. The
safety proﬁle and clinical data of all pts will be reported.
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CAREGIVER SUPPORT GROUP ON PEDIATRIC BONE MARROW TRANS-
PLANT UNIT: WHAT FAMILIES ARE TALKING ABOUT AND WHY THE
MEDICAL TEAM SHOULD LISTEN
Schmid, C.L.1, Calderon, K.S.1, Partin-Welch, P.H.1, Huber, H.1,
Robinson, N.S.1, Van Loon, R.A.2 1. Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH; 2. University of Cincinnati, Cincin-
nati, OH.
Prompted by families’ unrest in the Pediatric Blood and Marrow
Transplant Unit at Cincinnati Children’s Hospital Medical Cen-
ter, in the Spring of 2005, social workers began an hour-long,
weekly support group for caregivers of inpatients. Group atten-
dance has depended upon unit census and other factors such as
caregivers’ ability to leave the child in the room with an attendant.
Notable discussion points have emerged and the group has become
not only a support for caregivers but a guide for the medical team
on how to best assist families and patients through treatment and
recovery. The team’s understanding of the main, or previously
unrecognized, family issues is resulting in a better outcome for the
patients and caregivers. Overt and covert topics have emerged from
the group. Overt topics, or those “on the surface” or “expected” to
appear, remain consistent within almost each discussion. These
explicit topics include difﬁculty with distance from primary resi-
dence and managing the household, beneﬁt in connecting with
other caregivers on the unit, balancing siblings’ needs while caring
for sick child, and ﬁnancial strain. While it is necessary for the
medical team to be mindful of those struggles, it is potentially even
more important to consider covert issues that also make a powerful
impact and often go unnoticed. Covert topics, or those not as
readily voiced but shared among caregivers, may include self-care
and the need to be away from the child to express emotions,
responding to emotionally “needy” families on the unit, physical
impact of illness on the patient, fear of returning to hospital
following discharge, neediness of the ill child, comprehending
medical information and advocating for the child with the medical
team, how to successfully convey concerns to the team, and a
repeated expression in conﬁdence of the medical facility (poten-
tially stated for their own reassurance). In creating a safe environ-
ment for caregivers to share their concerns, struggles, and joys, the
medical team gains a better understanding of how to interpret
caregivers’ behavior and respond within a family-centered care
model. Subsequently, the patient’s treatment and recovery may go
more smoothly with families feeling better supported. Acknowl-
edging the multitude of strains and adjustments that accompany a
prolonged hospitalization will beneﬁt all involved with the pa-
tient’s care and, ultimately, the patient.
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GLUTAMINE SUPPLEMENTATION TO REDUCE ORAL MUCOSITIS IN
MULTIPLE MYELOMA PATIENTS RECEIVING HIGH-DOSE MELPHALAN
AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A FEASIBILITY
STUDY
Hansen, L.K.1, Smythe, P.A.1, Hansen, K.S.1, Gruenberg, D.R.1,
Callaway, D.1 1Legacy Good Samaritan Hospital, NW Marrow Trans-
plant Program, Portland, OR.
Oral mucositis is a common and distressing toxicity associated
with high dose Melphalan (HDM) and autologous stem cell
transplantation (ASCT). The amino acid, glutamine (GLN), has
been employed in an attempt to ameliorate oral mucositis in
various high dose chemotherapy regimens with mixed results.
This pilot study sought to evaluate the feasibility of adminis-
tering an oral GLN food supplement in patients with multiple
myeloma undergoing HDM and ASCT. Twelve patients (3
females and 9 males), median age 51, consented and enrolled in
the trial. GlutaSolve™ (Novartis) 15 gm bid was administered 4
days before the start of HDM and continued for at least 14 days
or 28 doses. Oral assessment and mucositis ratings were scored
by trained oncology nurses and physicians using the NCI Com-
mon Toxicity Criteria, version 3.0. Compliance with bid dosing,
tolerance of GLN, pain medication usage, total parenteral nu-
trition (TPN), and hospital length of stay (LOS) were measured.
The 12 study patients were compared to case controls matched
by gender, age, and presence or absence of renal dysfunction.
Results: The compliance rate for planned GLN doses was 91.3
%. Toxicities were minimal and were limited to occasional
nausea, vomiting, and mild abdominal pain after taking GLN.
Several patients developed aversion to ingesting GLN toward
the end of the treatment period. There were no cases of clinical
grades 3 or 4 oral mucositis observed in the 12 study subjects.
Median clinical mucositis score was grade 1 (mean  1.2) and
median functional mucositis score was grade 1 (mean  1.1).
Control patients had median clinical and functional mucositis
scores of 2 (mean  1.5) and 1 (mean  1.25), respectively. Only
1 study patient developed functional grade 3 mucositis (unable
to adequately aliment or hydrate orally), whereas 3 control
patients experienced grade 3 mucositis. None of the study pa-
tients received TPN and only 1 patient received parenteral
analgesia for oral discomfort. In comparison, 2 controls received
TPN due to oral mucositis and 4 received parenteral analgesia.
Average LOS was 16.8 days for study patients and 17.4 days for
controls. Conclusions: Oral GlutaSolve™ supplement is safe
and well tolerated in patients receiving HDM and ASCT for
treatment of multiple myeloma. Results of this pilot study sug-
gest this inexpensive form of GLN may reduce the severity of
oral mucositis and further study is warranted in patients receiv-
ing HDM and ASCT.
415
ANTIBACTERIAL PROPHYLAXIS DURING NEUTROPENIC PHASE IN AU-
TOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (APBSCT).
COMPARISON BETWEEN CIPROFLOXACIN  AMOXICILIN VS. LEVO-
FLOXACIN
Karduss, A.J.1, Gomez, L.R.1, Reyes, P.A.1, Jimenez, J.A.1,
Jaimes, F.2, Deossa, H.1 1. Instituto de Cancerologia - Clinica las
Americas, Medellin, Colombia; 2. Departamento de Medicina Interna -
Universidad de Antioquia, Medellin, Colombia.
From November 2002 to May 2004, the patients who received an
APBST had a prophylactic antibacterial regimen with ciproﬂoxacin
500 mg PO BID  amoxicilin 500 mg PO TID (group A). After
June 2004 our protocol changed to levaquin 500 mg PO daily
(group B). We compared the incidence of fever, infections, and
mortality related to the infections in these 2 groups. All the pa-
tients were in an individual room and they received ﬁlgrastin from
day 7 until neutrophils recovery. In case of fever a complete
physical exam, blood and urine cultures, and chest X-Ray were
done, and a Carbapenem was started. There were 20 patients in
group A, 13 men and 7 women, median age 38.90 years (15–67); 6
HD, 7 MM, 7 NHL. The average time with neutrophils 500 was
9.4 days and for engraftment was 11.4 days. Sixteen of twenty had
fever (80%), in 7 (43.7%) the cause was unknown, in 5 (31.2%) a
bacteria was found (E. coli [3], S. epidermidis[2]); 1 patient had
pneumonia caused by A. fumigatus, and 3 had engraftment syn-
drome and there were no deaths. Group B were 19 patients, 12
men and 7 women, median age 50.5 (24–60), 10 MM, 5 NHL, 4
HD. Average time with neutrophils500 was 9.47 days (7–12) and
for engraftment was 11.42 days (11–14). Seventeen patients had
fever (89.4%): 12 (70%) of unknown cause, in 3 (17.6%) a bacteria
was found (Burkhordelia cepacea [1], E. coli [2]), 1 had engraftment
syndrome and 1 pneumonia without germ. We had no deaths due
to infection, and 1 patient died secondary to VOD. For comparing
the groups a Fisher’s test was done, and there were no signiﬁcant
differences in frequency of fever cases (P  .365) nor bacteremia
cases (P  .378). These results remained non signiﬁcant after
adjustment with a logistic model for neutropenia days and the
average of days for engraftment between the groups; Wald test for
fever P .578 and for bacteremia, P .370. The prophylaxis daily
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cost was 16 USD in group A and 11.43 USD in group B. Con-
clusions: In this series of 39 patients the efﬁcacy of the single daily
dose of levoﬂoxacin was equivalent to the combination of ciclos-
porin plus amoxicilin as bacterial prophylaxis. A daily dose of
levaquin is more convenient and cheaper than the combination
therapy.
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G-CSF(FILGRASTIM) ON DAY 1 (DAY BEFORE STEM CELL INFUSION)
PROVIDES STABLE ENGRAFTMENT AND GOOD PROGRESSION FREE
AND OVERALL SURVIVAL (PFS AND OS) IN HEMATOPOEITIC STEM
CELL TRANSPLANTATION (HSCT)-TATA MEMORIAL CENTRE EXPERI-
ENCE
Bakshi, A.1, Sastry, P.S.R.K.1, Narayanan, P.1, Bhagwat, R.M.1,
Biswas, G.1, Mishra, B.1, Khadwal, A.1, Parikh, P.1 1Tata Memorial
Centre, Mumbai, Maharashtra, India.
Background: Recombinant human G-CSF hastens neutrophil
recovery following hematopoietic stem cell transplantation
(HSCT), thus accelerating engraftment.The optimal timing for
use of G-CSF in conjunction to HSCT needs to be established.We
present our data on effects of adding an extra dose of G-CSF
(ﬁlgrastim 5 micro gm/kg) on day -1 of HSCT. Patients and
Methods: Forty three consecutive patients who underwent HSCT
in one year period were given G-CSF on day 1 (day before stem
cell infusion) in addition to the regular doses from day 1 till
engraftment. Results: Among the 43 patients (median age 36
years), males were 34 and females 9 with 19 allograft and 24
autografts. The type of harvest was PBSC in 39, BM alone in 1 and
both in 3 cases. Disease wise distribution was AML-13, MM-8,
ALL-1, NHL-6, HL-5, CML-5, MDS-2, Aplastic Anemia, ALL,
and Ca nasopharynx 1 each. The median MNC and CD 34 doses
infused were 5.3  108/Kg and 2.26  106/Kg, respectively. Me-
dian days of Grade IV neutropenia was 11 (range 5–19) and that of
ANC 100 was 6 (range 2–19). Neutropenic fever was present for
a median of 10 days (range 4–19). Neutrophil engraftment and
platelet engraftment occurred at day 11(range 8–21) and day
21(range 11–73), respectively. Median number of packed cells
and platelets (SDP) transfused were 4 and 5, respectively. Mucosi-
tis was present for a median of 9 days with Grade III in 51% (n 
22) and Grade IV in 20% (n  9) patients. TPN was used in 76%
(n  33) patients with a median of 5 days. Median number of days
of antibiotics use was 10%, and 58% (n  25) needed 3 lines of
antibiotics. Antifungals were used in 60% (n  26), and 96% of its
use was empirical. Infections were documented in 40% (n  17).
Median days of hospitalization was 23 (range 13–38). Transplant
related mortality was 11.6% (2 auto and 3 allo). At 7 months the
overall survival is 78% with median follow up of 3.5 months.
Conclusions: Addition of G-CSF on day -1 of HSCT is safe and
provides stable engraftment and acceptable results in terms of
neutropenic fever, requirement of blood products, antibiotics,
TPN, and duration of hospital stay. Further randomized trials
comparing conventional scheduling of G-CSF (post infusion day
1 onwards) with the present schedule are warranted.
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PEGFILRASTIM FOR HEMATOPOIETIC RECOVERY AFTER AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
Patel, S.1, Sethi, S.1, Holter, J.1, Selby, G.1 1University of Oklahoma
Health Sciences Center, Oklahoma City, OK.
Filgrastim (FIL), granulocyte-colony stimulating factor, reduces
time to neutrophil engraftment, hospital stay, and antibiotic therapy.
FIL requires uncomfortable and inconvenient daily subcutaneous
(SC) injections. Pegﬁlgrastim (PFIL), while more expensive, requires
a single SC injection. Method/Results: An ongoing Phase II trial
compares PFIL 6 mg SC starting day 1 to FIL 480 mcg SC daily
starting day7 historical controls. Nine patients have been accrued to
date (10/10/05) (multiple myeloma 1; NHL 4; HD 4). Thirty
consectutive patients (MM 4; NHL 14; HD 12) were analyzed
as historical controls. ANC 500/mm3 was reached on the mean day
10 (range 9–12) for PFIL and day 12 (range 9–19) for FIL.
Platelets 50 K/mm3 were attained on a mean of day 13 (range
9–21) for PFIL versus day 27 (range 11–63) for FIL. No PFIL
patients required additional G-CSF. One patient had prolonged fever,
probably PFIL-related. Average cost of PFIL was $2681/patient;
average FIL cost was $2736/patient. Conclusions: Preliminary anal-
ysis indicates the equivalency of PFIL and FIL related to hematopoi-
etic recovery. Collection of engraftment, economic, and length-of-
stay data continues.
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THE DEVELOPMENT OF A SUCCESSFUL SATELLITE BONE MARROW
TRANSPLANT (BMT) UNIT AS A MODEL FOR HEALTH CARE OUTREACH
Schriber, J.1,2, Alvarnas, J.1,2, Kendrick, S.1, Dimpfel, S.1,
Sarkodee-Adoo, C.1,2, Forman, S.1,2 1. City of Hope Samaritan BMT
Unit, Phoenix, AZ; 2. City of Hope, Duarte, CA.
Recent innovations have expanded and evolved the ﬁeld of stem
cell transplantation. These changes and the increased complexity
of the ﬁeld have largely limited transplantation to traditional
academic centers. Despite being the ﬁfth largest metropolitan
city in the United States, in 1997 patients who lived in Phoenix,
Arizona, who required transplantation were required to travel
approximately 120 miles to the nearest transplant center. At that
time, prompted by local physicians, the Banner Health System
(the largest oncology provider in the city) partnered with the
City of Hope National Medical Center (COH), a nationally
recognized transplant center located in Duarte, California, to
form the City of Hope Samaritan BMT unit (COHS), a joint
venture between the 2 parties designed to build on each other’s
strengths. The COH provides the local physicians medical lead-
ership, clinical trials, and expertise with biomedical statistics.
Banner Health provides the physical structure, local adminis-
trative support, nursing, and all ancillary care services. The
programs are clinically fully integrated. Patients are discussed at
new patient conference via teleconference, pathology is re-
viewed at the COH, donor choices are made in cooperation with
the COH team, and patients are enrolled on joint clinical trials.
In addition, the Phoenix COH physicians actively participate in
disease committees and in weekly research rounds via telecon-
ference. COHS initially performed only autologous transplants
but now offers all forms of transplant services. To date 470
patients ( auto n  334, sibling allogeneic n  80, MUD n  55,
cord blood n  1) have been transplanted. In the past 2 years
approximatley 40% of patients underwent allogeneic transplan-
tation. Patient demographics are similar between the 2 institu-
tions. The 100 day transplant related mortality for the COHS
compares favorably to the COH (auto 1 vs 2%, allo 4 vs 8%, and
MUD 24 vs 29%). COHS is part of the CTN trials network
through its association with COH and is a member of the
SWOG. The program achieved full FACT accreditation in 2003
prior to the parent organization at COH. The success of this
model has been achieved because of similar corporate cultures,
close clinical integration, and oversight from a board composed
of members from each of the parent organization. We believe
this model can successfully be replicated if the parent organi-
zations share similar cultures and are committed to integrating
the programs clinically.
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